Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience

Nettis, Eustachio; Cegolon﻿﻿, Luca; Leo, Elisabetta; Canonica, Giorgio Walter; Detoraki, Aikaterini; Baiardini, Ilaria; Bisaccia, M.; Cancian, Mauro; Capretti, S.; Colombo, Giselda; Conte, Mariasole; Costantino, Maria Teresa; D’Alò, S.; D’Angelo, Audenzio; Feo, Giulia De; Paulis, Amato de; Gioacchino, Mario Di; Favero, Elisabetta; Fichera, S.; Gaeta, Francesco; Gangemi, Sebastiano; Gatta, Alessia; Heffler, Enrico; Rosa, Laura; Rizzini, Fabio Lodi; Macchia, Donatella; Macchia, Luigi; Maggi, Enrico; Martignago, A.; Minciullo, Paola Lucia; Mineni, Michela; Pannofino, A.; Parente, Roberta; Peveri, Silvia; Pucci, Stefano; Radice, Anna; Ridolo, Erminia; Romano, Antonino; Riggio, Oliviero; Savi, Eleonora; Senna, Gianenrico; Senter, Riccardo; Spadaro, Giuseppe; Stefanizzi, G; Vacca, Angelo; Vignoli, Aglaia; Villalta, Danilo; Yacoub, Mona‐Rita; Zaza, Ippolita

doi:10.1016/j.anai.2017.12.007

Cited by 22 publications

(28 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, in line with the literature (Damiani et al, ; Mandel et al, ; Nettis, ), clinical responses to the first, second, and third courses of omalizumab were similar. This characteristic is important because some patients are subject to relapses of moderate‐to‐severe degree after a course of treatment (mean disease‐free interval is about 2.5 months) and need periodic retreatment.…”

Section: Discussionsupporting

confidence: 92%

“…To the best of our knowledge, the time limit of 6 months for continuous treatment with omalizumab is defined only in Italian regulations. Thus, our data can be compared with those of studies performed by Italian authors (Bongiorno et al, ; Damiani et al, ; Mandel et al, ; Nettis, ; Romano et al, ). Romano et al reported a higher rate of complete resolution than in our study, but in a smaller population (6/9 patients, 67%), while Bongiorno et al reported, in a group of 18 patients, a 35.7% rate of complete resolution, followed by relapse within 1–4 months in all cases.…”

Section: Discussionmentioning

confidence: 82%

“…The reasons of the above differences are unknown. However, variability could be due, at least in part, to enrolment criteria: some authors studied CIU patients, while others included all types of spontaneous urticaria and even inducible urticaria, because omalizumab showed efficacy also in these forms of the disease (Arasi et al, ; Bongiorno et al, ; Damiani et al, ; Kaplan et al, ; Mandel et al, ; Nettis, ; Romano et al, ; Tharp et al, ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

From regulatory limitations to new opportunities: Real‐life experience on the effectiveness of short courses of omalizumab in the treatment of chronic idiopatic urticaria

Papaianni

Guarneri

Vaccaro

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Economic sustainability of long-term continuous treatment of antihistamine refractory chronic urticaria with omalizumab may be an issue. We assessed the efficacy of relatively short courses (5-6 months) of omalizumab in patients with chronic idiopathic urticaria (CIU). We retrospectively studied 40 patients (observed between June 2015 and January 2019) affected by moderate-to-severe CIU refractory to anti-H1 antihistamines (up to fourfold doses). Omalizumab was administered every 4 weeks for 24 weeks, then for 20 weeks in case of a relapse of moderate-to-severe degree, then again for 24 weeks in case of a second relapse. Monthly clinical evaluations were performed. Mean disease severity significantly dropped after 1 month and further decreased thereafter, with 30 complete remissions after the first course of treatment. In 2-4 months, 18 patients had a relapse of moderate-to-severe degree.The profile of response to the second course of omalizumab was similar to the first.A third course was necessary for seven patients. No adverse effects were recorded.Courses of 5-6 months of omalizumab may induce rapid significant improvement of urticaria and many prolonged complete remissions. In case of relapse, further courses show a similar profile of response and may induce additional long-term complete remissions. K E Y W O R D Schronic idiopathic urticaria, omalizumab, real life

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

From regulatory limitations to new opportunities: Real‐life experience on the effectiveness of short courses of omalizumab in the treatment of chronic idiopatic urticaria

Papaianni

Guarneri

Vaccaro

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Omalizumab treatment decreases the daily requirement of antihistamines and immunosuppressive drugs, which may exert systemic side effects in the majority of patients, indicating that decreasing the need for additional medication may also improve the quality of life of patients with CSU. Furthermore, Nettis et al reported that omalizumab is a good option for preventing polypharmacy in elderly patients (33).…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey

Bulur

Başkan

Özdemır

et al. 2018

Acta Dermatovenerologica Alpina Pannonica Et Adriatica

View full text Add to dashboard Cite

Introduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients. Methods: Study data were collected retrospectively from eight tertiary-care hospitals in Turkey. This study included 132 patients with chronic spontaneous urticaria that were resistant to H1 antihistamine treatment in a dose up to four times the licensed dose and were treated with 300 mg/month of omalizumab for 6 months. Results: The mean weekly urticarial activity score (UAS7) after omalizumab treatment improved significantly compared to the pretreatment score (p < 0.001). Treatment response was detected primarily in the 1st and 2nd months after treatment. No significant association was observed between omalizumab's treatment effectiveness and disease-related parameters or laboratory data. The mean dermatology life quality index was 23.12 ± 6.15 before treatment and decreased to 3.55 ± 3.60 6 months after treatment (p < 0.001). No side effects were reported in 89.4% (118) of the patients. Conclusion: This study showed that UAS7 decreased significantly and quality of life improved in omalizumab-treated patients. Moreover, treatment effectiveness was mainly observed in the first 2 months after treatment. However, no association was observed between omalizumab treatment effectiveness and disease-related parameters or laboratory data.

show abstract

“…Also, arterial thrombotic events including stroke, myocardial infarction, angina, ischemic heart disease, acute coronary syndrome and thrombosis are more frequent in patients with treated omalizumab [8]. Literature knowledge about the use of the drug in elderly patients is limited and reliability with the elderly has been shown as well [9]. We present a case of atrial fibrillation triggered by the use of omalizumab in an elderly chronic spontaneous urticaria patient with an atrial fibrillation history, who was under antiarrhythmic treatment and followed for sinus rhythm.…”

Section: Introductionmentioning

confidence: 99%

Triggering atrial fibrillation after omalizumab injection in a patient with chronic spontaneous urticarial. A case report

Çildağ

2019

Medicine and Pharmacy Reports

View full text Add to dashboard Cite

Introduction. Omalizumab is recommended as a third-line treatment in the treatment of chronic spontaneous urticaria. During omalizumab use, which has high efficacy and safety, the side effects observed are usually moderate and temporary. Here we discuss the triggering of atrial fibrillation following omalizumab injection.Case report. A 72-year-old female patient was treated with omalizumab 300 mg / day due to chronic spontaneous urticaria resistant to conventional treatments. Atrial fibrillation developed 6 hours after the second injection of omalizumab in the patient who had atrial fibrillation and who had been monitored with antiarrhythmic treatment and sinus rhythm for 1 year. The treatment was discontinued because omalizumab was thought to trigger atrial fibrillation, as no other reason to explain the triggering of atrial fibrillation could be found.Results and conclusion. There is no data in the literature on the use of omalizumab in patients with atrial fibrillation. Different side effects of biological treatments can be observed. In particular, omalizumab should be used with caution in elderly patients and patients with arrhythmia.

show abstract

Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience

Cited by 22 publications

References 28 publications

From regulatory limitations to new opportunities: Real‐life experience on the effectiveness of short courses of omalizumab in the treatment of chronic idiopatic urticaria

From regulatory limitations to new opportunities: Real‐life experience on the effectiveness of short courses of omalizumab in the treatment of chronic idiopatic urticaria

The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey

Triggering atrial fibrillation after omalizumab injection in a patient with chronic spontaneous urticarial. A case report

Contact Info

Product

Resources

About